Monday, October 3, 2022


Biotechnology News Magazine

BGI Americas Announces Strategic US partnership with Advaite: Launches Diagnostics Partnership Forum

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BGI Americas, a global leader in diagnostic testing, today announced a partnership with Advaite, a Pennsylvania-headquartered biotech company, as well as the launch of, a hub for diagnostics companies seeking partnerships through licensing, original equipment manufacturer (OEM) or distribution agreements.

The partnership will add Advaite’s RapCov™ Rapid COVID-19 Test to BGI’s growing portfolio of diagnostic testing solutions. The Advaite test is a CLIA-waived, lateral flow immunoassay for the qualitative detection of immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus in human fingerstick whole blood samples. One of the first U.S.-manufactured point-of-care serology tests for which the Food and Drug Administration has granted for emergency use authorization, the RapCov™ Rapid COVID-19 Test is simple to use and delivers highly accurate results in 15 minutes by eliminating the requirement to send the sample to a laboratory. The partnership allows BGI to combine Advaite’s proprietary handheld test with its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2, providing hospital systems and other health care facilities with both central laboratory and point-of-care CLIA-waived testing solutions.

“Our rapid antibody test kits provide an ideal solution for screening mass populations and help patients determine whether they were once infected with the disease without knowing,” said Karthik Musunuri, CEO of Advaite. “Partnering with BGI to supply hospitals and other health care facilities with our innovative tests was a no-brainer in helping fight this ongoing pandemic.”

The COVID-19 pandemic has underscored the global need for manufacturing and distribution of accessible and accurate diagnostic testing devices, and BGI’s launch of enables the company to partner with a broad range of organizations in the diagnostics testing space to advance diagnostic solutions. With proven commercial expertise and an established global footprint, partnering with BGI enables an organization to quickly and efficiently commercialize its in vitro diagnostic solutions.

“As one of the world’s largest suppliers of COVID-19 testing reagents and automation systems, we are thrilled to partner with Advaite to bring their groundbreaking testing solution to market and help stop the spread of the deadly coronavirus,” said Craig Hoechstetter, director of corporate development at BGI. “Not only does quick and easy testing alert individuals whether they are infected, it also enables them to get treated faster and take the necessary steps to minimize the spread of the virus to their colleagues, friends and families, ultimately saving lives. By offering end-to-end high-quality molecular and serology tests, we are providing a synergistic solution to tackling this pandemic head on by being one step ahead of the virus.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine